SUNNYVALE, Calif., Oct. 13, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company, in partnership with C-RAD AB (NASDAQ Stockholm: CRAD B), will showcase an important new option for improving the care of people diagnosed with breast cancer during the 2022 ASTRO (American Society for Radiation Oncology) Annual Meeting in San Antonio, Texas, October 23 – 26, 2022. Meeting attendees are invited to attend the U.S. unveiling of a new breast cancer treatment package* for the Radixact® System at the Accuray booth, #2586, on Sunday, October 23, 2022 at 10:30 am CT.

According to the National Cancer Institute, breast cancer is the most common cancer diagnosed in women in the U.S., other than skin cancers1. While rare, breast cancer can also occur in men2. Treatment for breast cancer represents more than 20 percent of cases seen by radiation oncology departments3,4.

The breast cancer treatment package is designed to enable medical care teams to provide an integrated and automated Deep Inspiration Breath Hold (DIBH) solution using Surface Guided Radiation Therapy (SGRT) that delivers ultra-precise treatments that enhance safety and speed. With the addition of this capability the Radixact System now offers the most comprehensive tool set in the industry by leveraging superior CT image quality from proprietary ClearRT™ imaging with the CT-linac capabilities of TomoHelical™ and TomoDirect™ deliveries in as quick as 10-minute treatment time slots.
"ASTRO 2022 marks an important milestone for our organization as we launch, with C-RAD, a new option for the Radixact System for treating the wide range of breast cancer patients. Breast cancer remains a significant women's health issue that with early detection and more precise treatment technology can have a major impact on extending and improving the quality of patients' lives. It seems appropriate to make this announcement during Breast Cancer Awareness Month, a time when people worldwide join together to raise awareness of improving early diagnosis and treatment options for this disease. This introduction is the result of our strong investment in R&D to deliver robust and differentiated products that are intended to improve lives," said Suzanne Winter, president and chief executive officer of Accuray.

"SGRT technology has proven its substantial benefits in hospitals and clinics around the world, as shown in the multitude of clinical research on the topic. We at C-RAD firmly believe surface tracking is becoming the standard of care," says Tim Thurn, CEO of C-RAD AB. "For breast cancer treatment in particular, our workflow for deep inspiration treatment has fantastic results, both for clinical teams but also for patients. The Accuray DIBH solution on Catalyst+ can be used for a multitude of indications, but for breast cancer treatments the seamless workflow allows deep inspiration treatment on the Radixact System to reduce the dose exposure to the heart amongst other benefits. The goggles as well as the in-room panels help guide the patient through their breathing cycles."

Rad Oncology Homepage